The FDA approved Eli Lilly’s oral SERD-based combination regimen, including Inluriyo (oral selective estrogen receptor degrader), for certain second-line metastatic breast cancer patients. The approval expands Lilly’s endocrine therapy portfolio with an all-oral treatment option tailored to a defined patient population. For clinicians and payers, the near-term impact is the introduction of an oral regimen intended to fit existing line-of-therapy frameworks for metastatic disease. For Lilly, the decision adds another regulated datapoint to support broader uptake as SERD strategies continue to evolve beyond first-line settings. Details on the exact indication parameters and label language weren’t fully specified in the provided brief, but the approval marks a direct regulatory milestone for the franchise.